Skip to main content
Nature medicine
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial.
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
Author Correction: Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial.
Urgent action is needed to confront artemisinin partial resistance in African malaria parasites.
Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial.
Robust airway microbiome signatures in acute respiratory failure and hospital-acquired pneumonia.
An integrated cell atlas of the lung in health and disease.
Redefining critical illness.
Reporting guidelines for human microbiome research: the STORMS checklist.
